A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 101
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : rCDI
Long Form : recurrent Clostridium difficile infection
No. Year Title Co-occurring Abbreviation
2020 A systematic review of economic evaluation in fecal microbiota transplantation. CUAs, EEs, FMT, IBD
2020 A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence. E-R, Emax, IgG-B, TTE
2020 Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II. ---
2020 Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease. CDI, CI, FMT, IBD, QALYs
2020 Cultivation and Genomics Prove Long-Term Colonization of Donor's Bifidobacteria in Recurrent Clostridioides difficile Patients Treated With Fecal Microbiota Transplantation. FMT, WGS
2020 Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. ---
2020 Efficacy of bezlotoxumab in trial participants infected with Clostridioides difficile strain BI associated with poor outcomes. REA
2020 Fecal Microbiota Transfer. FM, FMT
2020 Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection. FMT
10  2020 Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial. ARGs
11  2020 Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study. CDI, CI, HO-HCFA
12  2020 Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection. CDI, FMT
13  2020 Recurrent community-acquired Clostridium(Clostridioides)difficile infection in Serbianchildren. CA-CDI, RT
14  2020 Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials. ---
15  2020 Superiority of Higher-Volume Fresh Feces Compared to Lower-Volume Frozen Feces in Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Colitis. FMT
16  2020 Temporal Gut Microbial Changes Predict Recurrent Clostridiodes Difficile Infection in Patients With and Without Ulcerative Colitis. JSD, UC
17  2020 The Route to Palatable Fecal Microbiota Transplantation. FMT
18  2020 Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites. FMT
19  2019 Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders? FMT, IBD, IBS
20  2019 Cost savings following faecal microbiota transplantation for recurrent Clostridium difficile infection. CI, FMT
21  2019 Durable Long-Term Bacterial Engraftment following Encapsulated Fecal Microbiota Transplantation To Treat Clostridium difficile Infection. cFMT, cFMT, FMT
22  2019 Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway. FMT, FXR
23  2019 Fecal Microbial Transplantation impact on gut microbiota composition and metabolome, microbial translocation and T-lymphocyte immune activation in recurrent Clostridium difficile infection patients. FMT, LBP, MT
24  2019 Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease. FMT, IBD
25  2019 Fecal microbiota transplantation beyond Clostridioides difficile infections. FMT
26  2019 Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Lose Dose. FMT, FMTgr
27  2019 Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. FMT
28  2019 Fecal microbiota transplantation in children: current concepts. FMT
29  2019 Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection. CD, FMT
30  2019 Fecal Microbiota Transplantation: An Update on Clinical Practice. FMT
31  2019 Human transmission of Blastocystis by Fecal Microbiota Transplantation without development of gastrointestinal symptoms in recipients. FMT, ST
32  2019 Initial experience of fecal microbiota transplantation in gastrointestinal disease: A case series. FMT, UC
33  2019 Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. BSHs, FMT, UPLC-MS
34  2019 Minor Effect of Antibiotic Pre-treatment on the Engraftment of Donor Microbiota in Fecal Transplantation in Mice. AB, FMT
35  2019 Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent Clostridioides difficile infection. baiCD, FMT, LCA
36  2019 Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study. AOR, CI
37  2019 Repurposing an Old Drug for a New Epidemic: Ursodeoxycholic Acid to Prevent Recurrent Clostridioides difficile Infection. UDCA
38  2019 The impact of technical and clinical factors on fecal microbiota transfer outcomes for the treatment of recurrent Clostridioides difficile infections in Germany. FMT
39  2019 The success of fecal microbial transplantation in Clostridium difficile infection correlates with bacteriophage relative abundance in the donor: a retrospective cohort study. FMT
40  2019 Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile. BFT, FadA, FMT
41  2018 An Observational Cohort Study of Clostridium difficile Ribotype 027 and Recurrent Infection. ---
42  2018 Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children. FMT, IBD
43  2018 Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. ---
44  2018 Case series of successful treatment with fecal microbiota transplant (FMT) oral capsules mixed from multiple donors even in patients previously treated with FMT enemas for recurrent Clostridium difficile infection. FMT
45  2018 Classifying Fecal Microbiota Transplantation Failure: AnObservational Study Examining Timing and CharacteristicsofFecal Microbiota Transplantation Failures. FMT
46  2018 Clinical Efficacy and Microbiome Changes Following Fecal Microbiota Transplantation in Children With Recurrent Clostridium Difficile Infection. FMT
47  2018 Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis. CI, FMT, MT, OR, RCTs
48  2018 Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent Clostridium difficile Infection. CDI, FMT
49  2018 Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis. FMT
50  2018 Extended duration vancomycin in recurrent Clostridium difficile infection: a systematic review. EDV
51  2018 Fecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and results. FMT
52  2018 Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study. CDI, IQR
53  2018 Hospital readmission with Clostridium difficile infection as a secondary diagnosis is associated with worsened outcomes and greater revenue loss relative to principal diagnosis: A retrospective cohort study. CI, DRG, LOS, OR, PrCDI, SrCDI
54  2018 Medication Exposure and Risk of Recurrent Clostridium difficile Infection in Community-Dwelling Older People and Nursing Home Residents. EMR, NH
55  2018 Microbial taxonomic and metabolic alterations during faecal microbiota transplantation to treat Clostridium difficile infection. FMT
56  2018 Microbiologic factors affecting Clostridium difficile recurrence. ---
57  2018 Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. FMT
58  2018 Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel. iCDI
59  2018 Single centre clinical experience with fidaxomicin in the treatment of Clostridium difficile infection in Slovakia. CDI
60  2018 Small Intestinal Bacterial Overgrowth: Should Screening Be Included in the Pre-fecal Microbiota Transplantation Evaluation? FMT, GI, LBTs, SIBO, TI
61  2017 Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota. FMT
62  2017 Effect of Aging on the Composition of Fecal Microbiota in Donors for FMT and Its Impact on Clinical Outcomes. FMT
63  2017 Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. FMT
64  2017 Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications: A case series. E. coli, FMT, SIBO
65  2017 Fecal Microbiota Transplantation: Beyond Clostridium difficile. FMT
66  2017 Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection. FMT, UTIs
67  2017 Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. HRQoL
68  2017 Prediction of Recurrent Clostridium Difficile Infection Using Comprehensive Electronic Medical Records in an Integrated Healthcare Delivery System. EMR, iCDI
69  2017 Stable core virome despite variable microbiome after fecal transfer. FMT
70  2017 Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study. FMT
71  2017 The Impact of Recurrent Clostridium difficile Infection on Patients' Prevention Behaviors. ---
72  2017 Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. FMT, IBD
73  2017 Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study. ---
74  2016 Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. FMT
75  2016 Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation. FMT
76  2016 Cost Averted With Timely Fecal Microbiota Transplantation in the Management of Recurrent Clostridium difficile Infection in Alberta, Canada. FMT
77  2016 Environmental Contamination in Households of Patients with Recurrent Clostridium difficile Infection. FMT, PFGE
78  2016 Fecal microbial transplant for the treatment of pediatric inflammatory bowel disease. FMT, IBD
79  2016 Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection. ABR, FMT
80  2016 Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile Infection. FMT, GCMSG
81  2016 Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes. FMT
82  2016 Identification of Factors Impacting Recurrent Clostridium difficile Infection and Development of a Risk Evaluation Tool. CDI, PCR
83  2016 Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. FMT
84  2016 Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. 5-ASA, CI, HR, IBD
85  2016 Recurrent Clostridium difficile infection in intensive care unit patients. CDI, CI, COPD, ICU, MICU, OR, SICU
86  2015 Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. FMT, NS
87  2015 Fecal Microbiota Transplant: Respice, Adspice, Prospice. FMT, GI
88  2015 Fecal microbiota transplantation: current clinical efficacy and future prospects. FMT
89  2015 Risk Factors for Recurrent Clostridium difficile Infection in Children: A Nested Case-Control Study. PCR
90  2015 Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection--an observational cohort study. FMT
91  2015 [Fecal microbiota transplantation: review]. FMT
92  2015 [Use of fecal microbial transplantations for disease states in Israel]. FMT
93  2014 Development and validation of a recurrent Clostridium difficile risk-prediction model. iCDI
94  2014 Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile Infection. FMT
95  2014 Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome. CDI, FMT
96  2014 Fecal microbiota transplantation: a practical update for the infectious disease specialist. FDA, FMT, IND
97  2014 Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease. FMT
98  2014 Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study. CDI, iCDI
99  2013 Fecal microbiota transplantation: past, present and future. FMT, GI, IBD, IBS
100  2013 Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians. CDI, EIN, FMT